BioSpace News Archive

Quoin Pharmaceuticals Ltd. announces that the first patient has been dosed in its ongoing clinical trial evaluating the safety and efficacy of QRX003 as a treatment for Netherton Syndrome.

Ligand Pharmaceuticals Incorporated announced that at ’s Investor and Analyst Day event its executive management provided an overview of Ligand’s corporate structure and business following the successful spin-off of its OmniAb antibody discovery business, reviewed Ligand’s recent progress and near-term partner milestones and provided an outlook for financial growth.

Quanta Therapeutics, a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, today announced the appointment of Dr. Leonardo Faoro as Chief Medical Officer.

Chimeron Bio, an RNA company developing self-amplifying RNA vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced that Kevin Heyeck had been named Chief Executive Officer.

Optime Care, a member of the AscellaHealth Family of Companies, announced a contractual partnership with Rigel Pharmaceuticals, Inc., bringing its full suite patient support/HUB service capabilities to support Rezlidhia™, a recent FDA-approved treatment for adult patients with relapse or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.

The global stroke treatment market is expected to grow at a CAGR of 7.1% over the period between 2023 and 2032.

The global systemic inflammatory response syndrome treatment market size was valued at US$ 11.97 billion in 2022 and to reach valuation US$ 25.84 billion by 2032 with a CAGR of 8% from 2023 to 2032.

According to Nova one advisor, the Next-Generation Sequencing Services market size was accounted at USD 2.09 billion in 2022 and is predicted to be worth around USD 6.55 billion by 2032 with a notable CAGR of 19.3% from 2023 to 2032.

According to Nova one advisor, the global Hemoglobinopathies Market Size was valued at USD 10.1 billion in 2022 and is predicted to be worth USD 25.7 billion by 2032, with a CAGR of 13.80% from 2023 to 2032.

Sirnaomics Ltd. announced that its Executive Director Dr. Xiaochang Dai will deliver a keynote speech at BIOHK2022, the first major biotech conference to be held in Hong Kong since the outbreak of the COVID-19 pandemic.